135 related articles for article (PubMed ID: 33561557)
1. Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells.
Han X; Chen L; Hu Z; Chen L; Sun P; Wang Y; Liu Y
J Proteomics; 2021 Apr; 237():104122. PubMed ID: 33561557
[TBL] [Abstract][Full Text] [Related]
2. Identification of Up- and Down-Regulated Proteins in Pemetrexed-Resistant Human Lung Adenocarcinoma: Flavin Reductase and Calreticulin Play Key Roles in the Development of Pemetrexed-Associated Resistance.
Chou HC; Chen JY; Lin DY; Wen YF; Lin CC; Lin SH; Lin CH; Chung TW; Liao EC; Chen YJ; Wei YS; Tsai YT; Chan HL
J Proteome Res; 2015 Nov; 14(11):4907-20. PubMed ID: 26452990
[TBL] [Abstract][Full Text] [Related]
3. The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.
Ding X; Gu Y; Jin M; Guo X; Xue S; Tan C; Huang J; Yang W; Xue M; Zhou Q; Wang W; Zhang Y
Theranostics; 2020; 10(13):6048-6060. PubMed ID: 32483437
[No Abstract] [Full Text] [Related]
4. HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism.
Cui J; Xu F; Bai W; Zhao T; Hong J; Zuo W
J Transl Med; 2023 Feb; 21(1):125. PubMed ID: 36793108
[TBL] [Abstract][Full Text] [Related]
5. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
[TBL] [Abstract][Full Text] [Related]
6. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
[TBL] [Abstract][Full Text] [Related]
7. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
8. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells.
Okimoto T; Kotani H; Iida Y; Koyanagi A; Tanino R; Tsubata Y; Isobe T; Harada M
Cancer Sci; 2020 Jun; 111(6):1910-1920. PubMed ID: 32232903
[TBL] [Abstract][Full Text] [Related]
10. A novel lncRNA-hidden polypeptide regulates malignant phenotypes and pemetrexed sensitivity in A549 pulmonary adenocarcinoma cells.
Han X; Chen L; Sun P; Wang X; Zhao Q; Liao L; Lou D; Zhou N; Wang Y
Amino Acids; 2024 Feb; 56(1):15. PubMed ID: 38351332
[TBL] [Abstract][Full Text] [Related]
11. Quantitative proteomic approach to understand metabolic adaptation in non-small cell lung cancer.
Martín-Bernabé A; Cortés R; Lehmann SG; Seve M; Cascante M; Bourgoin-Voillard S
J Proteome Res; 2014 Nov; 13(11):4695-704. PubMed ID: 25029028
[TBL] [Abstract][Full Text] [Related]
12. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone alleviates pemetrexed-induced senescence in Non-Small-Cell Lung Cancer.
Ge H; Ke J; Xu N; Li H; Gong J; Li X; Song Y; Zhu H; Bai C
Food Chem Toxicol; 2018 Sep; 119():86-97. PubMed ID: 29753869
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
15. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS
Cells; 2019 Nov; 8(12):. PubMed ID: 31795298
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed induces G1 phase arrest and apoptosis through inhibiting Akt activation in human non small lung cancer cell line A549.
Wu DM; Zhang P; Xu GC; Tong AP; Zhou C; Lang JY; Wang CT
Asian Pac J Cancer Prev; 2015; 16(4):1507-13. PubMed ID: 25743822
[TBL] [Abstract][Full Text] [Related]
17. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
18. The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.
Chiu LY; Hsin IL; Yang TY; Sung WW; Chi JY; Chang JT; Ko JL; Sheu GT
Oncogene; 2017 Jan; 36(2):242-253. PubMed ID: 27270426
[TBL] [Abstract][Full Text] [Related]
19. Warburg effect enhanced by AKR1B10 promotes acquired resistance to pemetrexed in lung cancer-derived brain metastasis.
Duan W; Liu W; Xia S; Zhou Y; Tang M; Xu M; Lin M; Li X; Wang Q
J Transl Med; 2023 Aug; 21(1):547. PubMed ID: 37587486
[TBL] [Abstract][Full Text] [Related]
20. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells.
Chu H; Wu C; Zhao Q; Sun R; Yang K; Zhao B; Liu Y; Liang Z; Zhong S; Zhang L; Zhang Y
Carcinogenesis; 2021 May; 42(5):753-761. PubMed ID: 33677528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
